Related Post
In continuation of its national role in providing medicines of the highest quality, efficacy and reasonable prices, the Pharco B International Group – one of the largest pharmaceutical companies – announced the launch of three antibiotic drugs from the carbapenem group, which are effective in eliminating bacteria resistant to commonly used antibiotics, which contributes to saving The life of patients from severe infections in hospitals, after surgeries and in intensive care rooms, comes within the framework of the “Pharco B Global” strategy, which has been based since its establishment on providing the medical sector’s needs of medicines, and striving to produce them locally according to strict quality rules, whether local or international.
This came during a huge ceremony held at Abdeen Palace, in the presence of Dr. Ashraf Hatem, Professor of Chest Diseases at the Faculty of Medicine, Cairo University, former Minister of Health and Population and Chairman of the Health Committee of the House of Representatives, Dr. Sherine Helmy, Vice Chairman and Managing Director of Pharco Pharmaceutical Group, Dr. Mohamed Shawky, General Manager of Scientific Offices of Pharco B International, and a number of officials and senior doctors in Egypt, including Prof. Dr. Abdel Moati Hussein, Professor of General Surgery at the Faculty of Medicine, Cairo University, Prof. Dr. Adel Al-Ansari, Professor of Critical Medicine at the Faculty of Medicine, Ain Shams University, Prof. Yasser Mostafa, Professor of Chest Diseases, Faculty of Medicine, Ain Shams University Sun.
The production of these drugs came as a continuation of Pharco B’s vital role in localizing the pharmaceutical industry, maintaining Egypt’s regional leadership in the drug market, and employing more workers. The global Pharco-B group offers these drugs under a commercial name, Aqaree Ertapenem-PBI ( Effective Material Ertapenem ), and drug Ameropem ( Effective Material Meropenem), and drug Implatinze (Effective Material Imipenem – Cilastatin) with their different concentrations, and it obtained final approvals from the Egyptian Medicines Authority to put the drug on the market, after it met with great success when it was tested in major hospitals and showed a high efficacy that is no less efficient than its imported counterpart.
Pharco Group has established a special unit for the production of these drugs according to the latest technology in the world, which qualified it to obtain the two certificates ofISO and theGMP This unit was inaugurated by Prime Minister Dr. Mostafa Madbouly at the end of last year during the trial production of the drug.
In this context, Dr. Ashraf Hatem, the former Minister of Health and Population and Chairman of the Health Committee of the House of Representatives, stated that the “Carbapenem” series of antibiotics appeared more than 15 years ago, and the development of the active substance continued until we reached today to launch the third generation of antibiotics, as it is one of the most widely used drugs. Required in hospitals and intensive care departments to protect patients from bacteria present in hospitals, and the specified dose is taken only in the hospital under the supervision of a doctor.
For his part, Dr. Sherine Helmy, Vice Chairman and Managing Director of Pharco Pharmaceutical Group, said that Pharco B specializes in the production of biopharmaceuticals and antibiotics, and today we celebrate the launch of a new series of broad-spectrum antibiotics that are necessary in treating critical cases and must be available in all public hospitals. Especially because its absence poses a great danger to patients’ lives.
Dr. Mohamed Shawky, Director General of the Scientific Offices of Pharco B International, stated that the production of these antibiotics in Pharco B factories contributed to reducing the price of the medicinal product by 40%, which contributes to securing the local needs of these drugs and reducing dependence on the importer, thus reducing the import bill and increasing foreign exchange reserves.
Dr. Adel Al-Ansari, Professor of Critical Medicine at the Faculty of Medicine, Ain Shams University, stated that the antibiotic “carbapenem” is one of the effective compounds, which doctors reserve for cases where most other antibiotics fail, and is used to treat severe infections, and also works to resist resistant intestinal bacteria. For carbapenem antibiotics and most other commonly used antibiotics, sometimes all antibiotics are available. Dr. Abdel Moati added, most of the time, the risk of infection with intestinal bacteria increases, if the patient stays in the hospital for a long time, or uses devices such as respirators (ventilators) or catheters.
It is worth noting that the Pharco group of companies’ market share reached 10% of the volume of units consumed in Egypt by the end of 2020. While the production capacity of the Pharco Pharmaceutical Group exceeds 700 million pharmaceutical packages annually, of which more than 500 million packages are produced for consumption inside Egypt.
